Literature DB >> 9665726

Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor.

S L Stamps1, M C Fitzgerald, C P Whitman.   

Abstract

The cytokine macrophage migration inhibitory factor (MIF) mediates several immune and inflammatory processes through unknown or poorly understood mechanisms. The protein shares structural homology with two bacterial isomerases, 4-oxalocrotonate tautomerase (4-OT) and 5-(carboxymethyl)-2-hydroxymuconate isomerase (CHMI), and catalyzes the enolization of phenylpyruvate and the ketonization of (p-hydroxyphenyl)pyruvate. The amino-terminal proline has been identified as the catalytic base in both the 4-OT- and CHMI-catalyzed reactions. MIF also has an amino-terminal proline that has been implicated as a catalytic group in the MIF-catalyzed reaction. To delineate further the role of Pro-1 in the MIF-catalyzed reaction, affinity labeling studies were performed with 3-bromopyruvate (3-BP). The results of this study show that 3-BP acts as an active-site-directed irreversible inhibitor of the enzymatic activity and modifies one site per monomeric subunit. The inhibitor, as its lactyl derivative, is covalently attached to an 11 residue amino-terminal fragment, Pro-1 to Arg-11. The only reasonable site for alkylation within this peptide fragment is the amino-terminal proline. Because the pKa measured for the pH dependence of kinact/KI (5.7 +/- 0.2) and that measured for the pH dependence of the kcat/Km for the enolization of phenylpyruvate (6.0 +/- 0.1) are comparable and in reasonable agreement with the previously measured pKa of Pro-1 (5.6 +/- 0.1) obtained by its direct titration [Swope, M., Sun H.-W., Blake, P., and Lolis, E. (1998) EMBO J. (in press)], it is concluded that Pro-1 acts as the general base catalyst in the MIF-catalyzed reaction. The structural and mechanistic parallels place 4-OT, CHMI, and MIF in a superfamily of enzymes related by their ability to catalyze the keto-enol tautomerization of a pyruvyl moiety.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665726     DOI: 10.1021/bi9806955

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF).

Authors:  Alissa A Hare; Lin Leng; Sunilkumar Gandavadi; Xin Du; Zoe Cournia; Richard Bucala; William L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2010-08-03       Impact factor: 2.823

2.  Inactivation of tautomerase activity of macrophage migration inhibitory factor by sulforaphane: a potential biomarker for anti-inflammatory intervention.

Authors:  Zachary R Healy; Hua Liu; W David Holtzclaw; Paul Talalay
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05-20       Impact factor: 4.254

3.  Macrophage migration inhibitory factor covalently complexed with phenethyl isothiocyanate.

Authors:  Joel D A Tyndall; Hongqi Lue; Malcolm T Rutledge; Jurgen Bernhagen; Mark B Hampton; Sigurd M Wilbanks
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-08-29

4.  trans-3-Chloroacrylic acid dehalogenase from Pseudomonas pavonaceae 170 shares structural and mechanistic similarities with 4-oxalocrotonate tautomerase.

Authors:  G J Poelarends; R Saunier; D B Janssen
Journal:  J Bacteriol       Date:  2001-07       Impact factor: 3.490

5.  Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; William L Jorgensen
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

6.  Ostertagia ostertagi macrophage migration inhibitory factor is present in all developmental stages and may cross-regulate host functions through interaction with the host receptor.

Authors:  Guanggang Qu; Raymond Fetterer; Lin Leng; Xin Du; Dante Zarlenga; Zhiqiang Shen; Wenyu Han; Richard Bucala; Wenbin Tuo
Journal:  Int J Parasitol       Date:  2014-02-28       Impact factor: 3.981

7.  Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74.

Authors:  Roberto Meza-Romero; Gil Benedek; Kelley Jordan; Lin Leng; Georgios Pantouris; Elias Lolis; Richard Bucala; Arthur A Vandenbark
Journal:  Cytokine       Date:  2016-08-27       Impact factor: 3.861

8.  Direct modification of the proinflammatory cytokine macrophage migration inhibitory factor by dietary isothiocyanates.

Authors:  Kristin K Brown; Frances H Blaikie; Robin A J Smith; Joel D A Tyndall; Hongqi Lue; Jürgen Bernhagen; Christine C Winterbourn; Mark B Hampton
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

9.  A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation.

Authors:  Günter Fingerle-Rowson; Dayananda Rao Kaleswarapu; Corinna Schlander; Nazanin Kabgani; Tania Brocks; Nina Reinart; Raymonde Busch; Anke Schütz; Hongqi Lue; Xin Du; Aihua Liu; Huabao Xiong; Yibang Chen; Alice Nemajerova; Michael Hallek; Jürgen Bernhagen; Lin Leng; Richard Bucala
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

10.  Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening.

Authors:  Zoe Cournia; Lin Leng; Sunilkumar Gandavadi; Xin Du; Richard Bucala; William L Jorgensen
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.